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The major barrier to eradication of HIV infection is the 
latent viral reservoir that persists despite long-term 
highly active antiretroviral therapy (HAART). The main 
reason for the existence of latently infected cells is that 
proviral DNA becomes integrated into the cellular 
genome. Theoretically, the elimination of proviral DNA 
from every infected cell should therefore be able to cure 
HIV infection. This concept has been tested in studies 
that employed designed recombinases [1], zinc finger 
nucleases (ZFNs) and transcription activator-like effec-
tor nucleases (TALENs) bearing sequence-specific DNA-
binding modules that recognize HIV DNA sequences [2]. 
In addition, the recent development of the bacterial adap-
tive immune system CRISPR/Cas9 for editing of genes in 
mammalian cells [3, 4] quickly led to the use of this new 
genome editing technology to try to inhibit and eliminate 
infection by different viruses, including HIV-1 [5].
Cas9 is an endonuclease that cleaves double-stranded 
DNA in a sequence- specific manner. Cas9 associates 
with a guide RNA of which the first 20 nucleotides pair 
with the target DNA. In addition to this single guide 
RNA (sgRNA), Cas9 also needs to recognize a multi-
nucleotide region that is adjacent to the 3′ end of the 
target DNA, which is termed PAM (protospacer adja-
cent motif ). Several labs have designed sgRNAs to pro-
gram Cas9 to cleave different regions of HIV-1 DNA that 
include either essential viral genes or the viral long ter-
minal repeat (LTR). Profound suppression of HIV-1 pro-
duction and infection was reported in different cell types 
including latently infected CD4+ T cell lines, primary 
CD4+ T cells and induced human pluripotent stem cells 
[6–11].
Despite the promising possibility that CRISPR/Cas9 
could be used to inactivate or even delete proviral DNA 
from HIV-1 infected cells, an important unanswered 
question is whether and how HIV-1 might escape from 
the programmed CRISPR/Cas9 attack, a topic that is 
fundamental to attempts aimed at HIV treatment and 
prevention, including the use of small molecule-based 
antiretroviral therapy and HIV vaccines. Two recent pub-
lications by Wang G et al. 2016 and Wang Z et al. 2016 
have now provided unexpected answers to these ques-
tions [12, 13].
Both groups performed HIV-1 evolution experiments 
in CD4+ T cells that stably expressed both Cas9 and 
one of several sgRNAs that target different regions of 
the HIV-1 genome. Although prominent virus inhibition 
was apparent in transient assays, all infections yielded 
high levels of HIV-1 production after a variable time. 
Rapid escape was observed when non-conserved HIV-1 
sequences were attacked, but it did take longer for HIV-1 
to escape from Cas9/sgRNAs that targeted the more con-
served viral DNA sequences [12]. It could be expected 
that HIV-1 would change the sequence of the viral DNA 
that is targeted by sgRNA or the PAM sequence, knowing 
how HIV-1 escapes from a sequence-specific RNA inter-
ference attack [14–16]. Indeed, when the targeted viral 
DNA regions were sequenced, mutations were identified 
that interfered with sgRNA recognition.
Then came the unexpected observation. The major-
ity of the resistance mutations appeared to cluster at 
the site at which Cas9 was designed to cleave the viral 
DNA, even though the sgRNA binding site is much big-
ger. Another striking feature was the frequent occur-
rence of insertions and deletions (indels), at least for 
the less conserved viral target sequences. This suggests 
that these mutations are not the result of mistakes by 
the error-prone viral reverse transcriptase (RT) enzyme 
but rather represent mutations that are generated by the 
cellular non-homologous end joining (NHEJ) machin-
ery that repairs broken DNA (Fig.  1). This possibility 
was confirmed by deep sequencing analysis that showed 
that a number of the resistance-conferring mutations in 
the viral escape variants indeed matched the mutations 
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that were introduced into the viral DNA in CD4+ T 
cells that had been infected by HIV-1 for only 36 h [13]. 
Therefore, following sgRNA-targeted Cas9 cleavage, the 
error-prone NHEJ repair machinery generates a variety 
of mutations at the cleavage site. Some mutations abro-
gate the function of viral DNA and will not be selected, 
while others will be selected because they are not delete-
rious to the virus, yet generate resistance to Cas9/sgRNA 
attack because the target DNA sequence is changed. For 
some conserved targets, the indel type of mutations was 
apparently not compatible with virus replication, and in 
this case nucleotide substitutions appeared after a longer 
period that may have been introduced by NHEJ or regu-
lar RT mutagenesis.
Knowing how HIV-1 acquires resistance to Cas9/sgRNA 
may spur the development of strategies that might over-
come this unique viral escape mechanism. One solution 
may be to program Cas9 with multiple sgRNAs that tar-
get conserved viral DNA regions. Similar combinatorial 
strategies were effective for regular antiviral drugs and 
RNAi-mediated gene therapy to sustainably suppress viral 
replication [15]. Liao et al. did show that multiplexed tar-
geting of HIV-1 DNA led to much stronger suppression of 
HIV-1 infection, albeit that possible viral escape was not 
pursued [8]. Another approach might involve the engi-
neering of new Cas9 variants that are able to cleave DNA 
outside of the target sequence, so that the mutations aris-
ing from NHEJ repair will not prevent Cas9/sgRNA bind-
ing and DNA cleavage, thus not leading to viral resistance. 
Such an approach might be feasible given recent progress 
at creating Cas9 variants that are able to recognize differ-
ent PAMs, which demonstrates the flexibility of the sys-
tem [17–19]. Besides modifying Cas9, the advent of new 
CRISPR or CRISPR-like enzymes may also provide such 
a solution. For example, the newly discovered Cpf1 pro-
tein acts like Cas9, but in contrast to Cas9 that cleaves 
the DNA in the “seed” region adjacent to the PAM that is 
crucial for sgRNA recognition, Cpf1 cleaves in the more 
distal region of the target sequence that is less critical for 
sgRNA binding [20, 21]. Yet another anti-escape solution 
may be the suppression of the NHEJ activity, which can be 
achieved with anti-cancer drugs that target enzymes of the 
NHEJ machinery [22]. Solutions to overcome HIV-1 resist-
ance to CRISPR/Cas9 may also advance the application of 
CRISPR/Cas9 toward suppression of other viral infections.
The findings reported in these two recent studies should 
not impede the use of alternative CRISPR/Cas9 strategies 
to combat HIV infection. For example, CRISPR/Cas9 has 
been proposed for inactivation of the co-receptor genes 
CXCR4 and CCR5 to render cells refractory to HIV-1 
infection [23, 24]. If HIV-1 were able to escape from such 
a strategy, CRISPR/Cas9 would not directly contribute to 
the generation of resistance mutations. It is recognized 
that in vivo disruption of CXCR4, rather than CCR5, may 
interfere with the immune function of T cells. A second 
example is activation of latent HIV-1 proviruses by Cas9 
mutants that lack nuclease activity and that carry tran-
scription activation domains from transcription activa-
tor proteins [25–27]. When guided by sgRNAs to the 
HIV-1 LTR promoter, these Cas9 variants should be able 
to stimulate viral gene expression and drive HIV-1 out 
of latency. The lack of nuclease activity would preclude 
these Cas9 variants from facilitating viral escape.
In addition to viral escape, several other limitations 





















Fig. 1 HIV-1 escapes from Cas9/sgRNA. Cas9 is directed to HIV-1 DNA 
by sgRNA, then cleaves the target DNA at a position 3 nucleotides 
from the PAM. When the NHEJ machinery repairs the double-
stranded DNA break, short nucleotide insertions, deletions and 
substitutions are generated at the cleavage site. Many of these muta-
tions abrogate viral gene function and thus kill the virus. However, 
some mutations do not harm the virus and can promote viral escape. 
PAM, protospacer adjacent motif. sgRNA, single guide RNA. NHEJ 
non-homologous end joining. * substituted or inserted nucleotides. 
Δ, deleted nucleotides
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First, despite the fact that CRISPR/Cas9 has been shown 
to be effective in excision of HIV-1 proviral DNA either 
from acutely or latently infected cells [6–8, 10], none of 
these studies have tested this ability of CRISPR/Cas9 in 
the context of resting CD4 T cells from infected individu-
als. Second, we recognize that single gRNA-mediated 
suppression of HIV-1 replication is less pronounced 
compared to current therapies with small molecule 
inhibitors. It is possible that CRISPR/Cas9 could be com-
bined with HAART to clear latently infected cells, which 
HAART on its own has been unable to achieve. Unlike 
antiviral drugs, CRISPR/Cas9 as a gene therapy approach 
has the potential to durably protect cells against HIV-1. 
The in vivo delivery of the CRISPR/Cas9-encoding genes 
might be a challenge, but the lentiviral vector system 
is efficient at transducing both CD4 T cells and CD34 
hematopoietic stem cells. However, the integrating lenti-
viral vector might pose a risk of insertional oncogenesis. 
One recent solution to this challenge might be the use 
of virus-like particles that package Vpr-Cas9/sgRNA for 
transient delivery of this complex into target cells [28].
It is not readily clear whether some of these limitations 
of the CRISPR/Cas9 system can be overcome by switch-
ing to either the TALEN or ZFN systems. Although both 
the latter are more simple in that they do not have an 
RNA component, they are more difficult to program in 
terms of precise sequence specificity [29]. Importantly, 
ZFN-mediated cleavage of HIV-1 DNA can also lead to 
the generation of resistance mutations [30]. Nonetheless, 
knowledge that has been acquired using ZFN or TALEN 
to edit viral or cellular genes might facilitate the applica-
tion of CRISPR/Cas9 in similar settings.
Recognition of the limitations of the CRISPR/Cas9 sys-
tem will only advance its potential for future widespread 
application while suggesting strategies for improvement 
and optimization. The rapid progress in the CRISPR field 
and the discovery of new genetic tools ensures that this 
novel genome editing system will continue to provide 
surprises and excitement while leading to new and novel 
ways of attaining control of viral infections.
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